SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Encouraging early-stage ESMO results for Lillys investigational ovarian-cancer drug Sofe-M plus bevacizumab are drawing attention, with traders viewing the oncology pipeline as diversification beyond obesity treatments. The findings come from a small study, so their broader significance remains uncertain.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillars upcoming quarterly report is the main focus as shares pull back sharply, with traders debating whether strong backlog and data-center power demand can withstand already-high expectations. Some expect further downside if guidance or orders disappoint, while others view the oversold pullback as a buying opportunity.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Phase 2 results for pumitamig plus docetaxel in advanced lung cancer are drawing attention, with traders weighing the reported response rate and progression-free survival against questions about how durable the benefit will be. The reaction is tempered by broader concerns about BioNTechs earlier clinical setbacks and leadership transition.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

OUST is drawing attention for its sharp, volatile pullback, which traders variously blame on weakness in high-beta growth stocks or see as a buying opportunity. Bulls cite expanding lidar deploymentsincluding planned use of Rev8 sensors in John Deeres autonomous orchard machinesas support for Ousters Physical AI growth story, while skeptics question valuation, adoption and profitability.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Positive prostate-cancer trial results including a reported reduction in recurrence risk and a strong tumor response rateare driving attention to J&Js oncology pipeline. Traders are weighing whether the data can support further gains or is already priced in, with some watching whether shares hold their recent advance.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention after a steep selloff amid concern that Auvelitys launch for Alzheimers-related agitation and prescription growth may be slower than expected. Traders disagree on whether prescription data undercounts uptake in long-term-care settings and from samples; many are looking to the Q3 report for clarity and criticizing managements silence.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is drawing attention ahead of its earnings report as traders debate whether results can halt a sharp selloff tied to weakness in crypto and AI/data-center stocks. Bearish posts fear disappointing results and exposure to CoreWeave, while some investors see the decline as overdone and are positioning for a rebound.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is drawing attention for its weakness and repeated underperformance versus Bitcoin and other crypto-linked stocks amid volatile crypto prices. Traders debate whether the slide is mainly crypto-driven or reflects company-specific concerns, with Q3 results and revenue trends also in focus.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos shares have drawn attention amid a prolonged pullback despite solid results and AI-networking demand, with traders pointing to Piper Sandlers reduced price target and concerns about peak growth and valuation as possible reasons for weakness. Bulls counter that AI infrastructure demand supports the business and view the decline as a buying opportunity, while many traders remain frustrated by the stocks sluggish, range-bound action.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention after a prolonged selloff toward 52-week lows, with traders debating analyst downgrades, insider selling, valuation and whether the company can turn its defense-contract pipeline into stronger profits and cash flow. Some see the pullback as overdone given reported contract wins and drone, hypersonics and space demand, while others are cautious ahead of the Q3 report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Myomo (MYO) delivered earnings and revenue surprises of +30.00% and +14.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Myomo (MYO) Shows Fast-paced Momentum But Is Still a Bargain Stock

Myomo (MYO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Myomo (MYO)

Myomo (MYO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Myomo, Inc. (MYO) Reports Q1 Loss, Beats Revenue Estimates

Myomo (MYO) delivered earnings and revenue surprises of +21.74% and +8.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

Myomo (MYO) delivered earnings and revenue surprises of +5.88% and +11.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cresco Labs Inc. (CRLBF) Reports Q4 Loss, Beats Revenue Estimates

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of +14.16% and +0.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates

Myomo (MYO) delivered earnings and revenue surprises of +18.18% and +8.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Prestige Consumer Healthcare (PBH) Beats Q2 Earnings and Revenue Estimates

Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of +10.31% and +6.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Why Medical Device Maker Myomo’s Stock Crashed 42% In After-Hours Trading

Equity

The wearable medical robotics maker slashed its 2025 revenue forecast and posted a wider-than-expected quarterly loss due to weaker lead quality, slower conversions, and rising costs.

Myomo (MYO) delivered earnings and revenue surprises of 0.00% and +6.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. It is also involved in selling products through various other sales channels including through orthotics and prosthetics providers, veterans’ administration, and to distributors in certain accounts and geographic markets. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Burlington, MA.

Myomo Inc

Bearish Sentiment

Shares of Myomo plunged 42% in after-hours trading Monday after the maker of wearable medical robotics cut its 2025 revenue forecast and reported a bigger-than-expected loss in the second quarter (Q2).The company now sees full-year revenue of $40 million to $42 million, compared with prior guidance of $50 million to $53 million, and attributed the downward revision to lower-than-expected operating trends. It also sees third-quarter revenue of $9.5 million to $10 million.Revenue for the three months ended June 30 rose 28% from a year earlier to $9.7 million, above the Koyfin analyst estimate of $9.15 million. However, the company’s losses widened.&nbsp;Adjusted EBITDA loss was $4 million, missing analysts’ expectations of a $3.82 million loss. The company reported a net loss of $4.6 million, compared with expectations for a loss of $4.33 million in EBIT.&nbsp;Earnings per share were a loss of $0.11 per share, in line with estimates, on a GAAP basis.More than half of Q2 revenue came from Medicare Part B patients, helped by higher unit volumes and average selling prices.&nbsp;However, key forward indicators weakened: orders and insurance authorizations slipped 3% to 207 units, backlog fell 18% to 230 units, and gross margin narrowed to 62.7% from 70.8% due to higher material and overhead costs.CEO Paul R. Gudonis said performance was impacted by lower-quality leads resulting from changes to digital advertising, weaker conversion rates to pipeline additions and orders, and a cycle time issue where 40% to 50% of quarterly pipeline additions originate from leads generated more than a year prior.&nbsp;He noted that patient response, clinical profiles, and a stronger focus on outcomes were leading to more candidates being ruled ineligible for the MyoPro device.&nbsp;Much of the company’s 2025 advertising spend, he added, is expected to yield new patients in 2026 and beyond; however, recent actions and sustained ad spending are also expected to help improve operating metrics sooner.Operating expenses surged 65% to $10.6 million, driven by higher payroll, engineering costs, and a 162% increase in advertising outlays.&nbsp;Cash used in operations increased to $8.9 million from $1.9 million a year earlier, with non-recurring outflows, including $2.9 million in incentive payments and delayed insurance reimbursements, contributing to the shortfall.To curb costs, Myomo reduced its workforce by 8% in July and is scaling back spending on outside services, targeting at least $2 million in annual cash savings. The company ended the quarter with $15.5 million in cash, cash equivalents, and short-term investments, bolstered by $4 million in new borrowings.On Stocktwits, retail sentiment for Myomo was ‘extremely bullish’ early Tuesday amid a 4,700% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/MYO">Myomo’s stock</a> has declined by 72.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Myomo logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.21
Prev Close	$1.22
Open	$1.18
Dividend Yield	0.00%
50-Day Moving Average	$1.47
Beta	1.73
Avg. Volume	372,746.69
PE Ratio	-3.53

52-Week High	$1.89
52-Week Low	$0.605
Market Capitalization	$47.93M
EPS (Annual)	-$0.3721
Price to Book	8.21
Revenue Per Employee	$209,887.39

Feed

News

Sentiment

Earnings

Fundamentals

Info

MYO Fundamentals